Kenta Yamamoto

  • 1st Year GS (MSTP)

Why did you choose the University of Pittsburgh?

I chose to train at Pitt for the longstanding history of strong translational science, as well as the collaborative research environment in Immunology.  

Education & Training

  • University of Minnesota, Twin Cities BS in "Genetics, Cell Biology, and Development" 2019

Research Interests

Autoimmunity, cytokine signaling, Th17, transplant biology

Publications

Kararoudi MN, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, deSouza F, Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. “Optimization and Validation of CAR transduction into Human Primary NK Cells using CRISPR and AAV.” Cell Reports Methods, 2022. 

Walker SE, Sabin KZ, Gearhart M, Yamamoto K, Echeverri K. “Regulation of stem cell identity by miR-200a during spinal cord regeneration.” Development, 2022.

Tabdanov ED, Rodriguez-Merced NJ, Cartagena-Rivera AX, Puram VV, Callaway MK, Ensminger EA, Pomeroy EJ, Yamamoto K, Lahr WS, Webber BR, Moriarity BS, Zhovmer AS, Provenzano PP. “Enhancing T cell migration through structurally and mechanically complex tumor microenvironments.” Nature Communications, 2021.

Smeester BA, Draper G, Slipek NJ, Larsson A, Stratton N, Pomeroy EJ, Becklin K, Yamamoto K, Williams KB, Laoharawee K, Peterson JJ, Abrahante JE, Rathe SK, Mills LJ, Crosby MJ, Hudson WA, Rahrmann EP, Largaespada DA, Moriarity BS. “Implication of ZNF217 in accelerating tumor development and therapeutically targeting ZNF217-induced PI3K-AKT signaling for the treatment of metastatic osteosarcoma.” Molecular Cancer Therapeutics, 2020.

Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby M, Wang M, Rahrmann EP, Moriarity BS, Largaespada DA. “PLX3397 treatment inhibits constitutive CFS1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.” Bone, 2020.

Pomeroy EJ, Huzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby M, Lonetree C, Yamamoto K, Webber BR, Starr TK, Moriarity BS. “A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.” Molecular Therapy, 2019.